{"entity":{"id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","aka":["LAP100"],"tldr":"A phase 3 trial of capecitabine, fluorouracil (5-FU), gemcitabine, irinotecan (and liposomal irinotecan) and other drugs in pancreatic cancer, run by NRG Oncology, now recruiting.","summary":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06958328 by NRG Oncology, with a registry enrolment figure of 356 participants, started 2025-08-21 and due to reach its primary completion in 2030-10-21. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Capecitabine; Computed Tomography; Dose-escalated Radiation Therapy; Fluorouracil; Gemcitabine; Irinotecan Hydrochloride; Irinotecan Sucrosofate; Leucovorin Calcium; Magnetic Resonance Imaging; Nab-paclitaxel; Observation Activity; Oxaliplatin; Positron Emission Tomography; Questionnaire Administration; Radiation Therapy; Tumor Treating Fields Therapy. Conditions listed: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: \"* Pathologically (histologically or cytologically) proven diagnosis of pancreatic ductal adenocarcinoma\". Sites: Canada, United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06958328","url":"https://clinicaltrials.gov/study/NCT06958328"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","topoisomerase-inhibitors","ttfields"],"targets":[],"drugs":["capecitabine","fluorouracil","gemcitabine","irinotecan","leucovorin","nab-paclitaxel","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06958328","phase":"3","setting":"A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)","sponsor":"NRG Oncology","enrolled":356,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06958328/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}